Abstract 112P
Background
Colorectal liver metastasis (CLM) is classified as Resectable, Unresectable, and Borderline resectable (BR) based on Technical and Oncological categories, with recommended treatments tailored to each classification. However, there is currently no appropriate classification for instances of liver recurrence in CLM (r-CLM).
Methods
This study evaluated patients with CLM who underwent initial liver resection between 2006 and 2020 and subsequently experienced liver recurrences. We investigated the long-term outcomes and prognostic factors related to r-CLM.
Results
Out of 949 cases of initial liver resection, 650 cases experienced recurrence, and among them, 392 cases were identified as r-CLM. Early recurrence within one year (er-CLM) exhibited significantly poorer overall survival (OS) compared to instances of r-CLM recurring after one year (p < 0.0001). Nonetheless, even within the er-CLM group, resected er-CLM showed notably improved prognosis in comparison to the non-resected group (5-year OS: 48.1% vs. 0%, p < 0.0001). Multivariate analysis of er-CLM identified independent prognostic factors as the number of recurrent tumors (≥ 4) (HR, 1.95; 95% CI, 1.24-3.07; p = 0.004), tumor size (≥ 5cm) (HR, 3.77; 95% CI, 1.46-9.76; p = 0.006), and presence of extrahepatic diseases (HR, 1.71; 95% CI, 1.09-2.71; p = 0.021). Stratifying these factors for recurrence-Resectable and recurrence-BR cases resulted in a significant difference in prognosis between the two groups (59.5% vs. 26.5%, p < 0.001).
Conclusions
Even in cases of early recurrence within one year, repeat liver resection contributes to extending prognosis. Regardless of the background at the initial liver resection, the number of r-CLM, tumor size, and presence of extrahepatic diseases were identified independent prognostic factors. Tailoring appropriate treatment based on the characteristics of recurrent tumors holds the potential to enhance the prognosis for r-CLM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract